GEHC Pengajuan SEC - GE HealthCare Technologies Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300OI9J7XOWZMUN85
CIK	1932393

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GE HealthCare Technologies Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

July 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHCA
July 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2025 GE HEALTHCARE TECHNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi
July 30, 2025	EX-99	GE HealthCare reports second quarter 2025 financial results Exhibit 99 GE HealthCare reports second quarter 2025 financial results •Revenue growth was 3% year-over-year; Organic revenue growth* was 2% •Net income margin was 9.
July 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2025 GE HEALTHCARE TECHNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi
June 9, 2025	EX-4.1	Form of the Company’s 4.800% Senior Note due 2031 (incorporated by reference to Exhibit A of Exhibit 4.2 hereof). Exhibit 4.2 GE HEALTHCARE TECHNOLOGIES INC. and THE BANK OF NEW YORK MELLON, as Trustee THIRD SUPPLEMENTAL INDENTURE Dated as of June 9, 2025 to INDENTURE Dated as of November 22, 2022 Relating to $650,000,000 of 4.800% Notes due 2031 $850,000,000 of 5.500% Notes due 2035 i ii THIRD SUPPLEMENTAL INDENTURE THIRD SUPPLEMENTAL INDENTURE, dated as of June 9, 2025 (this “Third Supplemental Indenture”),
June 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2025 GE HEALTHCARE TECHNOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis
June 5, 2025	424B2	$1,500,000,000 GE HealthCare Technologies Inc. $650,000,000 4.800% Senior Notes due 2031 $850,000,000 5.500% Senior Notes due 2035 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 Prospectus Supplement to Prospectus dated June 28, 2024 $1,500,000,000 GE HealthCare Technologies Inc. $650,000,000 4.800% Senior Notes due 2031 $850,000,000 5.500% Senior Notes due 2035 We are offering $650,000,000 aggregate principal amount of 4.800% senior notes due 2031 (the “2031 notes”), and $850,000,000 aggregate
June 5, 2025	EX-FILING FEES	Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 GE HealthCare Technologies Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Eff
June 4, 2025	EX-1.1	, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC, as representatives of the se Execution Version GE HealthCare Technologies Inc. 4.800% Senior Notes due 2031 5.500% Senior Notes due 2035 Underwriting Agreement June 3, 2025 Citigroup Global Markets Inc. J.P. Morgan Securities LLC Morgan Stanley & Co. LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 1
June 4, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis
June 3, 2025	FWP	GE HealthCare Technologies Inc. June 3, 2025 $650,000,000 4.800% Senior Notes due 2031 $850,000,000 5.500% Senior Notes due 2035 PRICING TERM SHEET Issuer: GE HealthCare Technologies Inc. (the “Issuer”) Trade Date: June 3, 2025 Settlement Date: June FWP Filed Pursuant to Rule 433 Relating to Preliminary Prospectus Supplement dated June 3, 2025 To Prospectus dated June 28, 2024 Registration File No.
June 3, 2025	424B2	SUBJECT TO COMPLETION, DATED JUNE 3, 2025 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is
May 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2025 GE HEALTHCARE TECHNOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis
May 29, 2025	EX-1.01	GE HealthCare 2024 Conflict Minerals Report Exhibit 1.01 GE HEALTHCARE TECHNOLOGIES INC. Conflict Minerals Report Year ended December 31, 2024 1.Introduction GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our” or “we”) has prepared this Conflict Minerals Report (the “Report”) for the calendar year ended December 31, 2024, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). Terms used and not
May 29, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 (State or other jurisdiction of in UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 (State or other jurisdiction of incorporation) (Commission File Number) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) Frank Jimenez (833)
April 30, 2025	EX-99	GE HealthCare reports first quarter 2025 financial results Exhibit 99 GE HealthCare reports first quarter 2025 financial results •Revenue growth was 3% year-over-year; Organic revenue growth* was 4% •Net income margin was 11.
April 30, 2025	EX-10.8	025 Global Addendum. Exhibit 10.8 Global Addendum Global Information for the GE HealthCare Technologies Inc. (“GE HealthCare” or “Company”) 2023 Long-Term Incentive Plan (the “Plan”) January 2025 This Addendum provides additional terms and conditions of your grant in Section A and specific additional terms and conditions and/or notifications that apply to participants who reside, are employed and/or otherwise subject
April 30, 2025	EX-10.6	2025 GE HealthCare Performance Stock Unit Exhibit 10.6 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Performance Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date PSUs Granted Vesting Schedule Number of PSUs1 Vesting Date <> <> 100% The date in Q1 of <> on which the Committee (as defined below) certifies PSU performance 1Actual number of shares
April 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHC
April 30, 2025	EX-10.4	025 GE HealthCare Restric Exhibit 10.4 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date <> <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> 1. Grant. The Talent, Culture, and Compensation Committee (“Committee”) of the Bo
April 30, 2025	EX-10.3	with Roland Rott, dated as of June Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIV
April 30, 2025	EX-10.5	025 GE HealthCare Sto Exhibit 10.5 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Stock Option Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date Option Shares Granted Option Exercise Price* Option Expiration Date Vesting Schedule Number of Option Shares Vesting Date <> <> $ <> 1, <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> *Exercise price
April 30, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm
April 30, 2025	EX-10.7	althCare New Hire Restricted Stock Unit Grant Agreement. Exhibit 10.7 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare New Hire Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date <> <> 33% <> 33% <> 34% <> 1. Grant. The Talent, Culture, and Compensation Committee (“Committee”) of the Board of Di
April 10, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin
April 10, 2025	DEFA14A	Your Vote Counts! Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.co gehealthcarenotice2025 Your Vote Counts! Please check the meeting materials for any special requirements for meeting attendance.
March 31, 2025	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm
March 31, 2025	EX-10.1	, 2025, among the Registrant, as the borrower, JPMorgan Chase Bank, N.A., as the Administrative Agent, and the lenders party thereto Exhibit 10.1 Execution Version CREDIT AGREEMENT dated as of March 27, 2025 among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, JPMORGAN CHASE BANK, N.A., as the Administrative Agent, and The Lenders Party Hereto $3,000,000,000 REVOLVING CREDIT FACILITY JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and MORGAN STANLEY SENIO
March 31, 2025	EX-10.2	, 2025, among the Registrant, as the borrower, JPMorgan Chase Bank, N.A., as the Administrative Agent, and the lenders party thereto (incorporated by reference to Exhibit Exhibit 10.2 Execution Version 364-DAY REVOLVING CREDIT AGREEMENT dated as of March 27, 2025 among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, JPMORGAN CHASE BANK, N.A., as the Administrative Agent, and The Lenders Party Hereto $500,000,000 REVOLVING CREDIT FACILITY JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and MORG
February 13, 2025	EX-99	GE HealthCare reports fourth quarter and full year 2024 financial results Exhibit 99 GE HealthCare reports fourth quarter and full year 2024 financial results Fourth Quarter 2024 •Revenue growth was 2% year-over-year; Organic revenue growth* was 2% •Net income margin was 13.
February 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2025 GE HEALTHCARE TE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 13, 2025 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C
February 13, 2025	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 GE HealthCare Technologies Inc. Subsidiaries of Registrant As of December 31, 2024 LEGAL ENTITY STATE OR COUNTRY OF INCORPORATION OR ORGANIZATION Beijing GE Hualun Medical Equipment Company Limited China BK Medical ApS Denmark BK Medical Australia Pty Ltd. Australia BK Medical Austria GmbH Austria BK Medical France SAS France BK Medical Holding Company, Inc. Delaware BK Medical Italia
February 13, 2025	EX-19.1	ealthCare Technologies Inc. Securities Trading Policy. Exhibit 19.1 GE HEALTHCARE TECHNOLOGIES INC. SECURITIES TRADING POLICY Amended as of January 14, 2025 I.Purpose To describe the standards concerning the handling of non-public information relating to GE HealthCare Technologies Inc. and its subsidiaries (the “Company”) and the buying, selling, and other trading of securities of the Company. II.Persons Affected and Prohibited Transactions This Polic
February 13, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-41528 GE H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of incorporation o
December 12, 2024	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C
December 12, 2024	EX-10.1	364-Day Revolving Credit Agreement, dated as of December 11, 2024, among GE HealthCare Technologies Inc., Citibank, N.A., as Administrative Agent, and the lenders party thereto. Exhibit 10.1 Execution Version 364-DAY REVOLVING CREDIT AGREEMENT dated as of December 11, 2024 Among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, CITIBANK, N.A., as the Administrative Agent, And The Lenders Party Hereto $1,000,000,000 REVOLVING DOLLAR AND EURO CREDIT FACILITY CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and MORGAN STANLEY SENIOR
November 21, 2024	EX-99	2024 Outlook Exhibit 99 GE HealthCare hosts 2024 Investor Day: focus on innovation to deliver precision care and drive growth Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% CHICAGO — November 21, 2024 — GE HealthCare (Nasdaq: GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY.
November 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2024 GE HEALTHCARE TE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C
November 12, 2024	SC 13G/A	GEHC / GE HealthCare Technologies Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* GE HealthCare Technologies Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36266G107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
November 8, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C
November 8, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) GE HealthCare Technologies Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) GE HealthCare Technologies Inc.
November 8, 2024	EX-1.1	Underwriting Agreement, dated November 7, 2024, among GE HealthCare Technologies Inc., General Electric Company, Morgan Stanley & Co. LLC, as selling stockholder, and J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC, as underwriters. Exhibit 1.1 13,281,302 Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT November 7, 2024 November 7, 2024 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Morgan S
November 8, 2024	424B3	13,281,302 shares GE HealthCare Technologies Inc. Common Stock Filed pursuant to Rule 424(b)(3) File No. 333-277108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2024) 13,281,302 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 13,281,302 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement and the accompanying prospe
November 8, 2024	EX-99.1	GE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares Exhibit 99.1 GE HealthCare Technologies Inc. Prices Secondary Offering of 13,281,302 Shares November 7, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,281,302 shares of its common stock (the “GEHC Shares”). GE HealthCare is not sell
November 7, 2024	FWP	GE HealthCare Technologies Inc. Commences Secondary Offering of 13,281,302 Shares Free Writing Prospectus dated November 7, 2024 Filed Pursuant to Rule 433 Registration Statement No.
October 30, 2024	EX-99	GE HealthCare reports third quarter 2024 financial results Exhibit 99 GE HealthCare reports third quarter 2024 financial results •Revenue growth was 1% year-over-year; Organic revenue growth* was 1% •Net income margin was 9.
October 30, 2024	EX-99	GE HealthCare Recast Unaudited Historical Financial Information Reflecting the Company’s New Reportable Segment Structure Exhibit 99 GE HealthCare Recast Unaudited Historical Financial Information Reflecting the Company’s New Reportable Segment Structure Effective July 1, 2024, Image Guided Therapies (“IGT”), previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting.
October 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 GE HEALTHCARE TEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co
October 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEA
October 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 GE HEALTHCARE TEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co
October 22, 2024	SC 13G/A	GEHC / GE HealthCare Technologies Inc. / GENERAL ELECTRIC CO - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 eh24053401413ga3-gehc.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* GE HEALTHCARE TECHNOLOGIES INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 36266G 107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Sta
September 13, 2024	424B3	15,000,000 shares GE HealthCare Technologies Inc. Common Stock Filed pursuant to Rule 424(b)(3) File No. 333-277108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2024) 15,000,000 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 15,000,000 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement and the accompanying prospe
September 13, 2024	EX-1.1	Underwriting Agreement, dated September 12, 2024, among GE HealthCare Technologies Inc., General Electric Company, Morgan Stanley & Co. LLC, as selling stockholder, and Morgan Stanley & Co. LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein. Exhibit 1.1 Execution Version 15,000,000 Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT September 12, 2024 September 12, 2024 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: Morgan Stanley & Co. LLC, in its capacity as selling stoc
September 13, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) GE HealthCare Technologies Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) GE HealthCare Technologies Inc.
September 13, 2024	EX-99.1	GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 15,000,000 Shares Exhibit 99.1 GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 15,000,000 Shares September 12, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 15,000,000 shares of its common stock (the “GEHC Shares”) at a public offe
September 13, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 12, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (
September 12, 2024	FWP	GE HealthCare Technologies Inc. Commences Secondary Offering of 10,000,000 Shares Free Writing Prospectus dated September 12, 2024 Filed Pursuant to Rule 433 Registration Statement No.
August 15, 2024	EX-4.2	8-K filed with the SEC on August 15, 2024). Exhibit 4.2 GE HEALTHCARE TECHNOLOGIES INC. and THE BANK OF NEW YORK MELLON, as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of August 14, 2024 to INDENTURE Dated as of November 22, 2022 Relating to $1,000,000,000 of 4.800% Notes due 2029 TABLE OF CONTENTS Page ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION Section 1.01 References 1 Section 1.02 Definitions 2 ARTICLE TWO GEN
August 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2024 GE HEALTHCARE TECH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Com
August 9, 2024	424B2	GE HealthCare Technologies Inc. $1,000,000,000 4.800% Senior Notes due 2029 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 Prospectus Supplement to Prospectus dated June 28, 2024 GE HealthCare Technologies Inc. $1,000,000,000 4.800% Senior Notes due 2029 We are offering $1,000,000,000 aggregate principal amount of 4.800% senior notes due 2029 (the “notes”). Interest on the notes will be payable in cash semi-annually in arrears on February 1
August 9, 2024	EX-FILING FEES	Calculation of Filing Fee Tables 424 (b)(2) (Form Type) GE HealthCare Technologies Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424 (b)(2) (Form Type) GE HealthCare Technologies Inc.
August 9, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm
August 9, 2024	EX-1.1	Underwriting Agreement, dated August 7, 2024, among GE HealthCare Technologies Inc., and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein. Exhibit 1.1 GE HealthCare Technologies Inc. 4.800% Senior Notes due 2029 Underwriting Agreement August 7, 2024 Goldman Sachs & Co. LLC BofA Securities, Inc. Morgan Stanley & Co. LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282-2198 c/o BofA Securities, Inc. One Bryant Park Ne
August 7, 2024	FWP	GE HealthCare Technologies Inc. August 7, 2024 $1,000,000,000 4.800% Senior Notes due 2029 PRICING TERM SHEET Issuer: GE HealthCare Technologies Inc. (the “Issuer”) Trade Date: August 7, 2024 Settlement Date: August 14, 2024 (T+5) The Issuer expects FWP 1 d848981dfwp.htm FWP Filed Pursuant to Rule 433 Relating to Preliminary Prospectus Supplement dated August 7, 2024 To Prospectus dated June 28, 2024 Registration File No. 333-280584 GE HealthCare Technologies Inc. August 7, 2024 $1,000,000,000 4.800% Senior Notes due 2029 PRICING TERM SHEET Issuer: GE HealthCare Technologies Inc. (the “Issuer”) Trade Date: August 7, 2024 Settlement Date: Augu
August 7, 2024	424B2	SUBJECT TO COMPLETION, DATED AUGUST 7, 2024 424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-280584 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is
July 31, 2024	EX-99	GE HealthCare reports second quarter 2024 financial results Exhibit 99 GE HealthCare reports second quarter 2024 financial results •Revenues were flat year-over-year; Organic revenue growth* was 1% •Net income margin was 8.
July 31, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi
July 31, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHCA
June 28, 2024	S-3ASR	As filed with the U.S. Securities and Exchange Commission on June 28, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on June 28, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or Other Jurisdiction of Incor
June 28, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) GE HealthCare Technologies Inc.
June 28, 2024	EX-25.1	Form T-1 Statement of Eligibility of The Bank of New York Mellon, as trustee under the indenture dated as of November 22, 2022. Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382 (Ju
May 30, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 (State or other jurisdiction of in UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 (State or other jurisdiction of incorporation) (Commission File Number) 500 W. Monroe Street, Chicago, IL 60661 (Address of principal executive offices) (Zip Code) Frank Jimenez (833)
May 30, 2024	EX-1.01	Conflict Minerals Report Exhibit 1.01 GE HEALTHCARE TECHNOLOGIES INC. Conflict Minerals Report Year ended December 31, 2023 1.Introduction GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our” or “we”) has prepared this Conflict Minerals Report (the “Report”) for the calendar year ended December 31, 2023, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). Terms used and not
May 23, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 21, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis
April 30, 2024	EX-10.1	024 GE HealthCare Restricted Stock Unit Agreement ( Exhibit 10.1 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date <> <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> 1. Grant. The Talent, Culture, and Compensation Committee (“Committee”) of the Bo
April 30, 2024	EX-10.2	are Stock Option Grant Agreement (incorporated by reference to Exhibit 10.2 to the Registrant Exhibit 10.2 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Stock Option Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date Option Shares Granted Option Exercise Price* Option Expiration Date Vesting Schedule Number of Option Shares Vesting Date <> <> $ <> 1, <> 33% <> 1, <> 33% <> 1, <> 34% <> 1, <> *Exercise price
April 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 GE HEALTHCARE TECHN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm
April 30, 2024	EX-10.3	E HealthCare Performance Stock Unit Grant Exhibit 10.3 [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Performance Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date PSUs Granted Vesting Schedule Number of PSUs1 Vesting Date <> <> 100% The date in Q1 <> on which the Committee (as defined below) certifies PSU performance 1Actual number of shares of
April 30, 2024	EX-10.5	d by reference to Exhibit 10.5 to the Registrant Exhibit 10.5 Peter J. Arduini President and Chief Executive Officer GE Healthcare 500 West Monroe Street Chicago, IL 60661 9th September 2022 Mr Taha Kass-Hout Dear Taha We are pleased to offer you the position of Chief Science & Clinical Technology Officer (final title to be agreed to) for GE Healthcare. The details of this offer, which is contingent upon the successful completion of a background
April 30, 2024	EX-99	GE HealthCare Reports First Quarter 2024 Financial Results Exhibit 99 GE HealthCare Reports First Quarter 2024 Financial Results •Revenues declined 1% year-over-year; Organic revenue growth* was approximately flat •Net income margin was 8.
April 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHC
April 30, 2024	EX-10.4	lobal Addendum. Exhibit 10.4 Global Addendum Global Information for the GE HealthCare Technologies Inc. (“GE HealthCare” or “Company”) 2023 Long-Term Incentive Plan (the “Plan”) January 2024 This Addendum provides additional terms and conditions of your grant in Section A and specific additional terms and conditions and/or notifications that apply to participants who reside and/or are employed in one of the count
April 15, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi
April 4, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin
April 4, 2024	DEF 14A	COURTESY PROXY STATEMENT
April 4, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 2, 2024	SC 13G/A	GEHC / GE HealthCare Technologies Inc. / GENERAL ELECTRIC CO - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 eh24045986913ga2-gehc.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* GE HEALTHCARE TECHNOLOGIES INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 36266G 107 (CUSIP Number) March 31, 2024 (Date of Event Which Requires Filing of this Stateme
March 14, 2024	424B3	14,000,000 shares GE HealthCare Technologies Inc. Common Stock 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-277108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2024) 14,000,000 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 14,000,000 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement and
March 14, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 12, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm
March 14, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) GE HealthCare Technologies Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry For EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) GE HealthCare Technologies Inc.
March 14, 2024	EX-99.1	GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 14,000,000 Shares Exhibit 99.1 GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 14,000,000 Shares March 12, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 14,000,000 shares of its common stock (the “GEHC Shares”). The Offering was up
March 14, 2024	EX-1.1	Underwriting Agreement, dated March 12, 2024, among GE HealthCare Technologies Inc., General Electric Company, Morgan Stanley & Co. LLC, as selling stockholder, and Morgan Stanley & Co. LLC, as underwriter. Exhibit 1.1 Execution Version 14,000,000 Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT March 12, 2024 March 12, 2024 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Morgan Stanley & Co. LLC, in its capacity as selling stockholder (in such capacity, the “Selling Stockholder”) of the stock of GE HealthCare
March 12, 2024	FWP	GE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares Free Writing Prospectus dated March 12, 2024 Filed Pursuant to Rule 433 Registration Statement No.
March 11, 2024	SC 13G/A	GEHC / GE HealthCare Technologies Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: GE HealthCare Technologies Inc Title of Class of Securities: Common Stock CUSIP Number: 36266G107 Date of Event Which Requires Filing of this Statement: February 29, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule
February 16, 2024	EX-99.1	GE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares Exhibit 99.1 GE HealthCare Technologies Inc. Commences Secondary Offering of 13,000,000 Shares February 15, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of co
February 16, 2024	424B4	13,000,000 shares GE HealthCare Technologies Inc. Common Stock Table of Contents Filed pursuant to Rule 424(b)(4) File No. 333-277108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2024) 13,000,000 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 13,000,000 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement and the a
February 16, 2024	EX-1.1	Underwriting Agreement, dated February 15, 2024, among GE HealthCare Technologies Inc., General Electric Company, Morgan Stanley & Co. LLC, as selling stockholder, and Morgan Stanley & Co. LLC and BofA Securities, Inc., as representatives of the several underwriters named therein. Exhibit 1.1 13,000,000 Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT February 15, 2024 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Morgan Stanley & Co. LLC, in its capacity as selling stockholder (in such capacity, the “Selling Stockholder
February 16, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 15, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C
February 16, 2024	EX-99.2	GE HealthCare Technologies Inc. Prices Secondary Offering of 13,000,000 Shares Exhibit 99.2 GE HealthCare Technologies Inc. Prices Secondary Offering of 13,000,000 Shares February 16, 2024 CHICAGO — GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering pric
February 15, 2024	S-3ASR	As filed with the U.S. Securities and Exchange Commission on February 15, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on February 15, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or Other Jurisdiction of Inco
February 15, 2024	424B3	Subject to Completion Preliminary Prospectus Supplement dated February 15, 2024 Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-277108 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not per
February 15, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) GE HealthCare Technologies Inc.
February 13, 2024	SC 13G	US36266G1076 / GE HealthCare Technologies, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0999-gehealthcaretechnolog.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: GE HealthCare Technologies Inc Title of Class of Securities: Common Stock CUSIP Number: 36266G107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the ru
February 9, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) GE HealthCare Technologies Inc.
February 9, 2024	S-3ASR	As filed with the U.S. Securities and Exchange Commission on February 9, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on February 9, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or Other Jurisdiction of I
February 9, 2024	SC 13G/A	US36266G1076 / GE HealthCare Technologies, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* GE HealthCare Technologies Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36266G107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp
February 6, 2024	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 GE HealthCare Technologies Inc. Subsidiaries of Registrant LEGAL ENTITY STATE OR COUNTRY OF INCORPORATION OR ORGANIZATION Beijing GE Hualun Medical Equipment Company Limited China BK Medical ApS Denmark BK Medical Australia Pty Ltd. Australia BK Medical Austria GmbH Austria BK Medical Benelux NV Belgium BK Medical France SAS France BK Medical Holding Company, Inc. United States BK Med
February 6, 2024	EX-99	GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results Delivers Strong Financial and Operating Performance in First Year as Public Company Exhibit 99 GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results Delivers Strong Financial and Operating Performance in First Year as Public Company Fourth Quarter 2023 •Revenue growth was 5% year-over-year; Organic revenue growth* of 5% •Net income margin was 7.
February 6, 2024	EX-97.1	GE HealthCare Technologies Inc. Clawback Policy Exhibit 97.1 GE HEALTHCARE TECHNOLOGIES INC. CLAWBACK POLICY The Board of Directors (“Board”) of GE HealthCare Technologies Inc. (“Company”) has adopted this Clawback Policy (“Policy”) effective as of October 2, 2023, (i) in part to comply with, and it shall be interpreted consistent with, Section 10D of the Securities Exchange Act of 1934, as amended (“Exchange Act”), Rule 10D-1 promulgated under
February 6, 2024	EX-99	GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results Delivers Strong Financial and Operating Performance in First Year as Public Company Exhibit 99 GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results Delivers Strong Financial and Operating Performance in First Year as Public Company Fourth Quarter 2023 •Revenue growth was 5% year-over-year; Organic revenue growth* of 5% •Net income margin was 7.
February 6, 2024	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (
February 6, 2024	EX-99	GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results Delivers Strong Financial and Operating Performance in First Year as Public Company Exhibit 99 GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results Delivers Strong Financial and Operating Performance in First Year as Public Company Fourth Quarter 2023 •Revenue growth was 5% year-over-year; Organic revenue growth* of 5% •Net income margin was 7.
February 6, 2024	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (
February 6, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-41528 GE H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of incorporation o
February 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 6, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co
February 5, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2024 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co
February 2, 2024	SC 13G/A	US36266G1076 / GE HealthCare Technologies, Inc. / GENERAL ELECTRIC CO - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
December 15, 2023	EX-10.1	364-Day Revolving Credit Agreement, dated as of Exhibit 10.1 Execution Version 364-DAY REVOLVING CREDIT AGREEMENT dated as of December 13, 2023 Among GE HEALTHCARE TECHNOLOGIES INC., as the Borrower, CITIBANK, N.A., as the Administrative Agent, And The Lenders Party Hereto $1,000,000,000 REVOLVING DOLLAR AND EURO CREDIT FACILITY CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and MORGAN STANLEY SENIOR
December 15, 2023	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 13, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C
October 31, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEA
October 31, 2023	EX-10.1	s Quarterly Report on Form 10-Q filed with the SEC on October 31, 2023). Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS SEPARATION AGREEMENT & RELEASE HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. SUCH CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGIST
October 31, 2023	424B3	GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-272419 Prospectus Supplement No. 2 to Prospectus Dated June 7, 2023 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated June 7, 2023 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) by the selling stockho
October 31, 2023	424B3	GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-268797 Prospectus Supplement No. 5 to Prospectus Dated December 14, 2022 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) that may be
October 31, 2023	EX-99	GE HealthCare Reports Third Quarter 2023 Financial Results Exhibit 99 GE HealthCare Reports Third Quarter 2023 Financial Results •Revenue growth was 5% year-over-year; Organic revenue growth* of 6% •Net income attributable to GE HealthCare was $375 million versus $487 million for the prior year; Adjusted EBIT* $744 million versus $700 million •Net income margin was 7.
October 31, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co
July 25, 2023	EX-10.2	Offer Letter with James K. Saccaro, dated May 4, 2023 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on July 25, 2023). Exhibit 10.2 [Logo] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS OFFER LETTER HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TRE
July 25, 2023	424B3	GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-272419 Prospectus Supplement No. 1 to Prospectus Dated June 7, 2023 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated June 7, 2023 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) by the selling stockho
July 25, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHCA
July 25, 2023	424B3	GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-268797 Prospectus Supplement No. 4 to Prospectus Dated December 14, 2022 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) that may be
July 25, 2023	POS AM	Power of Attorney (contained on signature page hereto). POS AM Table of Contents As filed with the U.S. Securities and Exchange Commission on July 25, 2023. Registration No. 333-268797 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 3844 88-25
July 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2023 GE HEALTHCARE TECHNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi
July 25, 2023	EX-10.1	GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on July 25, 2023). Exhibit 10.1 GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team Section I.Purpose and Effective Date The GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team (the “Plan”) provides severance benefits under specified conditions to the CEO and Executives who experience a Qualifying Termination on or after April 1, 2023 (the “Effective Date”)
July 25, 2023	EX-99	GE HealthCare Reports Second Quarter 2023 Financial Results Exhibit 99 GE HealthCare Reports Second Quarter 2023 Financial Results •2Q Revenue growth of 7% year-over-year; Organic revenue growth* of 9% •2Q Net income attributable to GE HealthCare of $418 million versus $485 million for the prior year, Adjusted EBIT* of $711 million versus $719 million •2Q Diluted EPS was $0.
June 8, 2023	424B4	25,000,000 shares GE HealthCare Technologies Inc. Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-272419 PROSPECTUS SUPPLEMENT (To Prospectus dated June 7, 2023) 25,000,000 shares GE HealthCare Technologies Inc. Common Stock The selling stockholder identified in this prospectus supplement is offering 25,000,000 shares of our common stock. We are not selling any shares of common stock under this prospectus supplement
June 5, 2023	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 [●] Shares GE HEALTHCARE TECHNOLOGIES INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT [●], 2023 [●], 2023 Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: Morgan Stanley & Co. LLC, in its capacity as selling stockholder (in such capacity, the “Selling Stockholder”
June 5, 2023	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) GE HealthCare Technologies Inc.
June 5, 2023	S-1	As filed with the U.S. Securities and Exchange Commission on June 5, 2023. S-1 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 5, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 3844 88-2515116 (State or Other Jurisdiction of
June 5, 2023	CORRESP	GE HealthCare Technologies Inc. 500 W. Monroe Street Chicago, Illinois 60661 GE HealthCare Technologies Inc. 500 W. Monroe Street Chicago, Illinois 60661 June 5, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, DC 20549-6010 Attention: Jessica Ansart Re: GE HealthCare Technologies Inc. Registration Statement on Form S-1 (File No. 333-272419) Dear Ms. Ansart:
June 5, 2023	CORRESP	[Signature Page Follows] CORRESP June 5, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, DC 20549-6010 Attention: Jessica Ansart Re: GE HealthCare Technologies Inc. Registration Statement on Form S-1 (File No. 333-272419) Dear Ms. Ansart: In accordance with Rule 461 under the Securities Act of 1933, as amen
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 500 W. Monroe Street Chicago, IL 60661 (Address of principal execut
May 31, 2023	EX-1.01	2022 Conflict Minerals Report Exhibit 1.01 General Electric Company 2022 Conflict Minerals Report Introduction General Electric Company (“GE” or the “Company”) has prepared this Conflict Minerals Report (“Report”) for the year ended December 31, 2022, as provided for in Rule 13p-1 of the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Conflict Minerals Rule”). GE manufactures a wide range of produc
May 25, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis
May 10, 2023	SC 13G	US36266G1076 / GE HealthCare Technologies, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GE HealthCare Technologies Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36266G107 (CUSIP Number) April 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
May 9, 2023	EX-99	GE HealthCare Names James Saccaro Vice President and Chief Financial Officer Exhibit 99 GE HealthCare Names James Saccaro Vice President and Chief Financial Officer Chicago, IL – May 9, 2023 – GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, has named James "Jay” Saccaro as vice president and chief financial officer (CFO), succeeding Helmut Zodl who is remaining with the Company to lead special projects regarding separation from GE.
May 9, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of Registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis
May 9, 2023	424B3	$8,250,000,000 GE HealthCare Technologies Inc. Exchange Offers for $1,000,000,000 5.550% Senior Notes due 2024 $1,500,000,000 5.600% Senior Notes due 2025 $1,750,000,000 5.650% Senior Notes due 2027 $1,250,000,000 5.857% Senior Notes due 2030 $1,750, 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No.
May 4, 2023	CORRESP	GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, IL 60661 CORRESP GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, IL 60661 May 4, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park and Abby Adams Re: GE HealthCare Technologies Inc. Registration Statement on Form S-4 (File No. 333-271435) Dear Ms. Park and Ms. Adams: In accordance with Rule 461 of t
April 25, 2023	EX-10.9	GE HealthCare Non-Employee Director Compensation and Benefits Plan (incorporated by reference to Exhibit 10.9 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on April 25, 2023). Exhibit 10.9 Non-Employee Director Compensation and Benefits Plan Compensation Element Amount Board Cash* $125,000 Board Equity Restricted Stock Units (RSUs)* $200,000 Committee Chair Cash Retainer* Audit $ 25,000 Compensation $ 20,000 Nominating & Governance $ 15,000 Board Leadership Cash Retainer* Lead Independent Director $ 40,000 Non-Executive Chair $130,000 Stock Ownership Requirements 5x Boa
April 25, 2023	EX-10.13	Offer Letter with Frank R. Jimenez, dated February 4, 2022 (incorporated by reference to Exhibit 10.13 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on April 25, 2023). Exhibit 10.13 GE Healthcare Peter J. Arduini President and Chief Executive Officer 500 West Monroe Street Chicago, IL 60661 February 4, 2022 Mr. Frank Jimenez Dear Frank: We are pleased to offer you the position of Group Vice President & General Counsel for GE Healthcare. The details of this offer, which is contingent upon the successful completion of a background check, reference check, and a dru
April 25, 2023	CORRESP	Paul, Weiss, Rifkind, Wharton & Garrison LLP 1285 Avenue of the Americas New York, New York 10019-6064 April 25, 2023 CORRESP Paul, Weiss, Rifkind, Wharton & Garrison LLP 1285 Avenue of the Americas New York, New York 10019-6064 April 25, 2023 Via EDGAR Securities and Exchange Commission 100 F Street, N.
April 25, 2023	EX-10.12	0 (incorporated by reference to Exhibit 10 Exhibit 10.12 Katya Kruglova Vice President, Human Resources GE Healthcare Improving Lives in the Moments that Matter November 25th, 2020 Helmut Zodl Dear Helmut, We are pleased to offer you the position of Vice President-Chief Financial Officer, in GE Healthcare (the “business,” within General Electric Company, the “company”) on a mutual agreed start date (your “start date”). This position will b
April 25, 2023	10-Q	Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41528 GE HEALTHC
April 25, 2023	EX-10.14	Offer Letter with Betty D. Larson, dated January 21, 2022. Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS OFFER LETTER HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS: (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS
April 25, 2023	EX-25	Form T-1 Statement of Eligibility of The Bank of New York Mellon to act as trustee under the Indenture, dated as of November 22, 2022.+ EX-25 Exhibit 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☒ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) THE BANK OF NEW YORK MELLON (Exact name of trustee as specified in its charter) New York 13-5160382
April 25, 2023	EX-99	GE HealthCare Reports First Quarter 2023 Financial Results Exhibit 99 GE HealthCare Reports First Quarter 2023 Financial Results •1Q Revenue growth of 8% year-over-year; Organic revenue* growth of 12% •1Q Net income attributable to GE HealthCare of $372 million versus $389 million for the prior year, Adjusted EBIT* of $664 million versus $599 million •1Q Diluted EPS was $0.
April 25, 2023	EX-FILING FEES	Filing Fee Table.+ Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) GE HealthCare Technologies Inc.
April 25, 2023	EX-10.15	Employment Contract with Jan Makela, dated February 24, 2023 (incorporated by reference to Exhibit 10.15 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on April 25, 2023). Exhibit 10.15 EMPLOYMENT CONTRACT Between: GE Healthcare Limited (“the Company”) And: Jan Makela (“you”) YOUR KEY TERMS Job Title Base Salary President & CEO, Healthcare Imaging reporting to Peter Arduini, President & CEO, GE Healthcare £530,000 per year payable monthly on or about the 15th. This is also known as your Reference Pay. Incentive Plan Continuing membership of the One GE HealthCare Ann
April 25, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm
April 25, 2023	CORRESP	GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, Illinois 60661 CORRESP GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, Illinois 60661 April 25, 2023 BY EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 GE HealthCare Technologies Inc. Registration Statement on Form S-4 Ladies and Gentlemen: GE HealthCare Technologies Inc. (the “Company”) has filed a registration statement on Form S-
April 25, 2023	EX-10.11	GE HealthCare 2023 LTIP Form of Director Deferred Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.11 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on April 25, 2023). Exhibit 10.11 [Logo] [Date] Equity Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“LTIP”) GE HealthCare Deferred Stock Unit Agreement (“Agreement”) For <> Grant Date Deferred Stock Units (“DSUs”) Date <> 1. Grant. The individual named in this Agreement (“Recipient”) elected to defer cash retainers otherwise payable for service on the Board of Directors of GE HealthCare Te
April 25, 2023	S-4	As filed with the Securities and Exchange Commission on April 25, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Techno Table of Contents As filed with the Securities and Exchange Commission on April 25, 2023 Registration No.
April 25, 2023	EX-99.1	Letter of Transmittal.+ EX-99.1 Exhibit 99.1 LETTER OF TRANSMITTAL To Tender for Exchange $1,000,000,000 aggregate principal amount 5.550% Senior Notes due 2024 (CUSIP Numbers 36267VAA1 / U3644QAA3) $1,500,000,000 aggregate principal amount 5.600% Senior Notes due 2025 (CUSIP Numbers 36267VAC7 / U3644QAB1) $1,750,000,000 aggregate principal amount 5.650% Senior Notes due 2027 (CUSIP Numbers 36267VAE3 / U3644QAC9) $1,250,
April 25, 2023	424B3	GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-268797 Prospectus Supplement No. 3 to Prospectus Dated December 14, 2022 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) that may be
April 25, 2023	EX-10.10	GE HealthCare 2023 LTIP Form of Director Restricted Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.10 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on April 25, 2023). Exhibit 10.10 [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> Grant Date RSUs Granted Vesting Date Date <> the earlier of the date of the Company’s next annual stockholder meeting or the one-year anniversary of the Grant Date 1. Grant. The Board of Directors of
April 18, 2023	DRS	Confidential Treatment Requested by GE HealthCare Technologies Inc. Pursuant to 17 C.F.R. § 200.83 As confidentially submitted to the U.S. Securities and Exchange Commission on April 17, 2023. This draft registration statement has not been publicly f Table of Contents Confidential Treatment Requested by GE HealthCare Technologies Inc.
April 5, 2023	424B3	GE HealthCare Technologies Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-268797 Prospectus Supplement No. 2 (to Prospectus dated December 14, 2022) GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) th
April 5, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 5, 2023	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin
March 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 23, 2023 GE HEALTHCARE TECHN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 23, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Comm
March 24, 2023	EX-10.1	GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on March 24, 2023). Exhibit 10.1 GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team Section I.Purpose and Effective Date The GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team (the “Plan”) provides severance benefits under specified conditions to the CEO and Executives who experience a Qualifying Termination on or after April 1, 2023 (the “Effective Date”)
March 3, 2023	EX-10.2	GE HealthCare Stock Option Grant Agreement (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on March 3, 2023). Exhibit 10.2 FORM OF AWARD FOR SECTION 16 OFFICERS [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare [Year] Stock Option Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date Option Shares Granted Option Exercise Price* Option Expiration Date Vesting Schedule Number of Option Shares Vesting Date <> <> $ [Month] 1,
March 3, 2023	EX-10.3	GE HealthCare Performance Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on March 3, 2023). Exhibit 10.3 FORM OF AWARD FOR SECTION 16 OFFICERS OF COMPANY [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare [Year] Performance Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date PSUs Granted Vesting Schedule Number of PSUs1 Vesting Date <> <> 100% The date in Q1 [Year] on which the Committee (as d
March 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2023 GE HEALTHCARE TECHNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commi
March 3, 2023	EX-10.1	GE HealthCare Restricted Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on March 3, 2023). Exhibit 10.1 FORM OF AWARD FOR SECTION 16 OFFICERS OF COMPANY [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Technologies [Year] Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date <> <> 33% [Month] 1, [Year] 33% [Month] 1, [Year]
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2023 GE HEALTHCARE TE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (C
February 15, 2023	424B3	GE HealthCare Technologies Inc. Filed pursuant to Rule 424(b)(3) File No. 333-268797 Prospectus Supplement No. 1 to Prospectus Dated December 14, 2022 GE HealthCare Technologies Inc. This prospectus supplement supplements information contained in the prospectus dated December 14, 2022 (the “Prospectus”), relating to the offering shares of common stock of GE HealthCare Technologies Inc. (the “Company,” “we” or “our”) that may be
February 15, 2023	EX-10.11	GE HealthCare 2023 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.11 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 15, 2023). Exhibit 10.11 GE HEALTHCARE TECHNOLOGIES INC. 2023 LONG-TERM INCENTIVE PLAN Section I.Purpose The purpose of this GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan is to attract, retain and motivate employees, officers, non-employee directors and other service providers of GE HealthCare Technologies Inc. (the “Company”). Stock- and performance-based compensation provided under this Pla
February 15, 2023	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Table S-8 (Form Type) GE HealthCare Technologies Inc.
February 15, 2023	EX-4.4	Exhibit 4.4 Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit is a part, GE HealthCare Technologies Inc. ( “GE HealthCare,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exc
February 15, 2023	S-8	As filed with the Securities and Exchange Commission on February 15, 2023 As filed with the Securities and Exchange Commission on February 15, 2023 Registration No.
February 15, 2023	EX-21.1	Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 15, 2023). Exhibit 21.1 GE HealthCare Technologies Inc. Subsidiaries of Registrant LEGAL ENTITY STATE OR COUNTRY OF INCORPORATION OR ORGANIZATION Beijing GE Hualun Medical Equipment Company Limited China BK Medical ApS Denmark BK Medical Australia Pty Ltd. Australia BK Medical Austria GmbH Austria BK Medical Benelux NV Belgium BK Medical France SAS France BK Medical Holding Company, Inc. Delaware BK Medical
February 15, 2023	10-K	United States Securities and Exchange Commission WASHINGTON, D.C. 20549 FORM 10-K ☑ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 Commission file number 001-41528 GE H United States Securities and Exchange Commission WASHINGTON, D.C. 20549 FORM 10-K ☑ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 Commission file number 001-41528 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of incorporation o
February 10, 2023	SC 13G	GEHC / GE Healthcare Holding LLC / GENERAL ELECTRIC CO - SCHEDULE 13G Passive Investment SC 13G 1 eh23032119713g-gehc.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GE HEALTHCARE TECHNOLOGIES INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 36266G 107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) C
February 3, 2023	EX-10.4	One GE HealthCare Annual Bonus Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 3, 2023). Exhibit 10.4 One GE HealthCare Annual Bonus Plan (effective January 1, 2023) I. Purpose The Plan is an annual performance-based bonus plan that incentivizes and rewards eligible employees of the Company for delivering on the Company’s financial, operating and strategic goals during a Plan Year. The Plan supersedes the terms of prior annual bonus plans, including the Annual Executive Incentive Plan
February 3, 2023	EX-10.1	GE HealthCare Founders Restricted Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 3, 2023). Exhibit 10.1 FORM OF AWARD FOR SECTION 16 OFFICERS OF COMPANY [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Founders Restricted Stock Unit Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date RSUs Granted Vesting Schedule Number of RSUs Vesting Date February 1, 2023 <> 50% February 1, 2025 50% February 1, 2026
February 3, 2023	EX-10.3	Global Addendum (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 3, 2023). Exhibit 10.3 FORM OF AWARD FOR SECTION 16 OFFICERS Global Addendum Global Information for the GE HealthCare Technologies Inc. (“GE HealthCare” or “Company”) 2023 Long-Term Incentive Plan (the “Plan”) January 2023 This Addendum provides additional terms and conditions of your grant in Section A and specific additional information that applies to residents of the countries listed below in Section B.
February 3, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co
February 3, 2023	EX-10.2	GE HealthCare Founders Stock Option Grant Agreement (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 3, 2023). Exhibit 10.2 FORM OF AWARD FOR SECTION 16 OFFICERS [Logo] [Date] Equity Grant Agreement GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan (“Plan”) GE HealthCare Founders Stock Option Grant Agreement (“Grant Agreement”) For <> (“Grantee”) Grant Date Option Shares Granted Option Exercise Price* Option Expiration Date Vesting Schedule Number of Option Shares Vesting Date February 1, 2023
January 30, 2023	EX-99	GE HealthCare Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99 GE HealthCare Reports Fourth Quarter and Full Year 2022 Financial Results •4Q Revenues up 8% year-over-year, Organic revenues* up 13% •4Q Net income of $554 million versus $564 million for the prior year, Adjusted EBIT* of $844 million versus $827 million •4Q EPS were $1.
January 30, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Co
January 10, 2023	EX-99.1	GE HealthCare Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Results; Introduces 2023 Outlook Strong Revenue Growth Driven by Fulfillment and Demand Exhibit 99.1 GE HealthCare Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Results; Introduces 2023 Outlook Strong Revenue Growth Driven by Fulfillment and Demand CHICAGO, IL – January 10, 2023 – GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022. The Company also issue
January 10, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact name of registrant as specified in its charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Com
January 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2023 GE HEALTHCARE TEC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2023 GE HEALTHCARE TECHNOLOGIES INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-41528 88-2515116 (State or other jurisdiction of incorporation) (Commis
January 4, 2023	EX-10.3	Employee Matters Agreement, dated January 2, 2023, by and between General Electric Company and the Registrant (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 4, 2023). EX-10.3 Exhibit 10.3 EMPLOYEE MATTERS AGREEMENT THIS EMPLOYEE MATTERS AGREEMENT (“Employee Matters Agreement”) is executed effective as of January 2, 2023, by and between General Electric Company, a New York corporation (“Parent”) and GE HealthCare Technologies Inc., a Delaware corporation (“SpinCo”) (collectively, the “Parties”). WHEREAS, the Parties have entered into a Separation and Distributio
January 4, 2023	EX-10.6	Stockholder and Registration Rights Agreement, dated January 2, 2023, by and between General Electric Company and the Registrant (incorporated by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 4, 2023). EX-10.6 8 d386556dex106.htm EX-10.6 Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS:
January 4, 2023	EX-10.4	Trademark License Agreement, dated December 31, 2022, by and between General Electric Company and GE HealthCare Imaging Holding Inc. (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 4, 2023).† EX-10.4 Exhibit 10.4 TRADEMARK LICENSE AGREEMENT Name and Address of Licensee: GE HealthCare Imaging Holding Inc. 3000 N Grandview Blvd Waukesha, WI 53188 Attn: [*] E-mail: [] with a copy (which will not constitute notice) to: GE HealthCare 500 West Monroe Street Chicago, IL 60661 Attn: [] E-mail: [*] Name and Address of Parent: General Electric Company Trademark Operation 901 Main Ave N
January 4, 2023	EX-10.1	Transition Services Agreement, dated January 2, 2023, by and between General Electric Company and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 4, 2023).† EX-10.1 Exhibit 10.1 TRANSITION SERVICES AGREEMENT BETWEEN GENERAL ELECTRIC COMPANY AND GE HEALTHCARE TECHNOLOGIES INC. DATED JANUARY 2, 2023 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS TRANSITION SERVICES AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTA
January 4, 2023	EX-2.1	Separation and Distribution Agreement, dated November 7, 2022, by and between General Electric Company and the Registrant, as amended (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 4, 2023). EX-2.1 Exhibit 2.1 SEPARATION AND DISTRIBUTION AGREEMENT by and between GENERAL ELECTRIC COMPANY and GE HEALTHCARE HOLDING LLC Dated as of November 7, 2022 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS SEPARATION AND DISTRIBUTION AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT OF 1
January 4, 2023	EX-99.1	GE HealthCare Completes Spin-Off and Begins Trading on Nasdaq EX-99.1 Exhibit 99.1 GE HealthCare Completes Spin-Off and Begins Trading on Nasdaq • A leader in precision care, focused on creating a world where healthcare has no limits • Attractive financial profile supported by commitment to accelerating growth, margin expansion, and free cash flow generation through organic investment, business optimization, and disciplined capital allocation • Trading on Na
January 4, 2023	EX-10.5	Real Estate Matters Agreement, dated January 2, 2023, by and between General Electric Company and the Registrant (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 4, 2023). EX-10.5 Exhibit 10.5 REAL ESTATE MATTERS AGREEMENT This REAL ESTATE MATTERS AGREEMENT (this “Agreement”) is entered into on January 2, 2023 by and between General Electric Company, a New York corporation (“Parent”), and GE HealthCare Technologies Inc., a Delaware corporation (“SpinCo”). R E C I T A L S: WHEREAS, in accordance with that certain Separation and Distribution Agreement dated as of Nove
January 4, 2023	EX-10.2	Tax Matters Agreement, dated January 2, 2023, by and between General Electric Company and the Registrant (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 4, 2023). EX-10.2 4 d386556dex102.htm EX-10.2 Exhibit 10.2 TAX MATTERS AGREEMENT by and between GENERAL ELECTRIC COMPANY and GE HEALTHCARE TECHNOLOGIES INC. Dated as of January 2, 2023 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS TAX MATTERS AGREEMENT HAS BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***], PURSUANT TO REGULATION S-K ITEM 601(B) OF THE SECURITIES ACT O
December 29, 2022	EX-99.7	Consent of Risa Lavizzo-Mourey as Director Nominee. Exhibit 99.7 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-8 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 29, 2022	EX-3.2	Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 29, 2022). EX-3.2 3 d439598dex32.htm EX-3.2 Exhibit 3.2 BYLAWS of GE HEALTHCARE TECHNOLOGIES INC. (A Delaware Corporation) TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II STOCKHOLDERS 3 ARTICLE III DIRECTORS 12 ARTICLE IV COMMITTEES OF THE BOARD 29 ARTICLE V OFFICERS 29 ARTICLE VI INDEMNIFICATION AND PAYMENT OF EXPENSES 32 ARTICLE VII GENERAL PROVISIONS 34 i ARTICLE I DEFINITIONS As used in these B
December 29, 2022	EX-FILING FEES	Filing Fee Table. EX-FILING FEES 15 d433417dexfilingfees.htm EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table S-8 (Form Type) GE HealthCare Technologies Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fe
December 29, 2022	EX-99.2	Consent of Peter J. Arduini as Director Nominee. Exhibit 99.2 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-8 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 29, 2022	EX-99.1	Consent of H. Lawrence Culp, Jr. as Director Nominee. Exhibit 99.1 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-8 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 29, 2022	EX-99.9	Consent of Phoebe L. Yang as Director Nominee. Exhibit 99.9 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the Registration Statement on Form S-8 (the “Registration Statement”) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 29, 2022	EX-99.4	Consent of Lloyd W. Howell, Jr. as Director Nominee. EX-99.4 9 d433417dex994.htm EX-99.4 Exhibit 99.4 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the Registration Statement on Form S-8 (the “Registration Statement”) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will beco
December 29, 2022	S-1/A	As filed with the Securities and Exchange Commission on December 29, 2022 S-1/A As filed with the Securities and Exchange Commission on December 29, 2022 Registration Statement No.
December 29, 2022	EX-99.6	Consent of Tomislav Mihaljevic as Director Nominee. Exhibit 99.6 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act??), in connection with the Registration Statement on Form S-8 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Hold
December 29, 2022	EX-99.3	Consent of Rodney F. Hochman as Director Nominee. EX-99.3 8 d433417dex993.htm EX-99.3 Exhibit 99.3 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the Registration Statement on Form S-8 (the “Registration Statement”) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will beco
December 29, 2022	EX-99.8	Consent of William J. Stromberg as Director Nominee. Exhibit 99.8 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-8 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 29, 2022	EX-99.5	Consent of Anne T. Madden as Director Nominee. Exhibit 99.5 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the Registration Statement on Form S-8 (the “Registration Statement”) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 29, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits 8-K 1 d439598d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2022 GE HEALTHCARE TECHNOLOGIES INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-41528 88-2515116 (State or other jurisdiction
December 29, 2022	EX-3.1	Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant EX-3.1 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF GE HEALTHCARE TECHNOLOGIES INC. (a Delaware corporation) The undersigned incorporator, in order to form a corporation under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: ARTICLE I NAME The name of the corporation is GE HealthCare Technologies Inc. (the “Corporation”). ARTICLE II AGENT The address o
December 29, 2022	S-8	As filed with the Securities and Exchange Commission on December 29, 2022 S-8 1 d433417ds8.htm S-8 As filed with the Securities and Exchange Commission on December 29, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) Delaware 88-2515116 (State or other jurisdiction of inc
December 29, 2022	CORRESP	GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, IL 60661 CORRESP 1 filename1.htm GE HEALTHCARE TECHNOLOGIES INC. 500 W. Monroe Street Chicago, IL 60661 December 29, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park and Abby Adams Re: GE HealthCare Technologies Inc. Form S-1 File No. 333-268797 Dear Ms. Park and Ms. Adams: In accordance with Rule 461 of the Sec
December 14, 2022	EX-99.8	Consent William J. Stromberg as Director Nominee. Exhibit 99.8 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-1 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 GE Healthcare Holding LLC* (Exact Name of Registrant as Specified in its Charter) Delaware 001-41528 88-2515116 (State or Other Jurisdiction of Incorporation) (Commi
December 14, 2022	EX-10.14	GE HealthCare Mirror 1990 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.14 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on December 14, 2022). Exhibit 10.14 GE HEALTHCARE TECHNOLOGIES INC. MIRROR 1990 LONG-TERM INCENTIVE PLAN SECTION 1. PURPOSE The purpose of this GE HealthCare Technologies Inc. Mirror 1990 Long-Term Incentive Plan (the ?Plan?) is to assume on the Effective Date (as defined below), as a result of the spin-off of GE?s healthcare business (the ?Spin-Off?), awards in GE HealthCare Technologies Inc. (the ?Company?) as a resu
December 14, 2022	EX-99.3	Consent of Rodney F. Hochman as Director Nominee. Exhibit 99.3 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-1 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 14, 2022	S-1	As filed with the Securities and Exchange Commission on December 14, 2022 Table of Contents As filed with the Securities and Exchange Commission on December 14, 2022 Registration Statement No.
December 14, 2022	EX-99.4	Consent of Lloyd W. Howell, Jr. as Director Nominee. Exhibit 99.4 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-1 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 14, 2022	EX-99.9	Consent of Phoebe L. Yang as Director Nominee. Exhibit 99.9 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-1 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 14, 2022	EX-FILING FEES	Filing Fee Table. EXHIBIT 107 Calculation of Filing Fee Table S-1 (Form Type) GE Healthcare Holding LLC (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.
December 14, 2022	EX-99.1	Consent of H. Lawrence Culp, Jr. as Director Nominee. Exhibit 99.1 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-1 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 14, 2022	EX-10.12	GE HealthCare Mirror 2022 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.12 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on December 14, 2022). Exhibit 10.12 GE HEALTHCARE TECHNOLOGIES INC. MIRROR 2022 LONG-TERM INCENTIVE PLAN Section I. Purpose The purpose of this GE HealthCare Technologies Inc. Mirror 2022 Long-Term Incentive Plan is to assume on the Effective Date (as defined below), as a result of the spin-off of GE?s healthcare business (the ?Spin-Off?), awards in GE HealthCare Technologies Inc. as a result of the conversion of award
December 14, 2022	EX-10.11	GE HealthCare 2023 Long-Term Incentive Plan. Exhibit 10.11 GE HEALTHCARE TECHNOLOGIES INC. 2023 LONG-TERM INCENTIVE PLAN Section I. Purpose The purpose of this GE HealthCare Technologies Inc. 2023 Long-Term Incentive Plan is to attract, retain and motivate employees, officers, non-employee directors and other service providers of GE HealthCare Technologies Inc. (the ?Company?). Stock- and performance-based compensation provided under this Pl
December 14, 2022	EX-99.5	Consent of Anne T. Madden as Director Nominee. Exhibit 99.5 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act??), in connection with the Registration Statement on Form S-1 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Hold
December 14, 2022	EX-10.13	GE HealthCare Mirror 2007 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.13 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on December 14, 2022). Exhibit 10.13 GE HealthCare Technologies Inc. Mirror 2007 Long-Term Incentive Plan SECTION 1. PURPOSE The purpose of this GE HealthCare Technologies Inc. Mirror 2007 Long-Term Incentive Plan (the ?Plan?) is to assume on the Effective Date (as defined below), as a result of the spin-off of GE?s healthcare business (the ?Spin-Off?), awards in GE HealthCare Technologies Inc. (the ?Company?) as a resu
December 14, 2022	EX-99.6	Consent of Tomislav Mihaljevic as Director Nominee. Exhibit 99.6 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-1 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 14, 2022	EX-99.7	Consent of Risa Lavizzo-Mourey as Director Nominee. Exhibit 99.7 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-1 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 14, 2022	EX-99.2	Consent of Peter J. Arduini as Director Nominee. Exhibit 99.2 CONSENT OF DIRECTOR NOMINEE Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), in connection with the Registration Statement on Form S-1 (the ?Registration Statement?) of GE Healthcare Holding LLC, the undersigned hereby consents to being named and described as a person who will become a director of GE Healthcare Holdi
December 8, 2022	EX-99.1	INFORMATION STATEMENT GE Healthcare Holding LLC Common Stock (par value $0.01 per share) Table of Contents Exhibit 99.1 December 8, 2022 Dear GE Shareholders: In November 2021, we announced our plans to transform GE by forming three independent, investment-grade industry leaders with sustainability at their core. We will spin off GE HealthCare first in early 2023; combine our renewable energy, power, and digital businesses into one business, GE Vernova, to be launched as an independen
December 8, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 GE Healthcare Holding LLC* (Exact Name of Registrant as Specified in its Charter) Delaware 001-41528 88-2515116 (State or Other Jurisdiction of Incorporation) (Commis
December 6, 2022	CORRESP	GE HEALTHCARE HOLDING LLC 500 W. Monroe Street Chicago, IL 60661 GE HEALTHCARE HOLDING LLC 500 W. Monroe Street Chicago, IL 60661 December 6, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes and Tim Buchmiller Re: GE Healthcare Holding LLC Form 10-12B File No. 001-41528 Dear Messrs. Howes and Buchmiller: In accordance with Rule 12d1-2 promulgated under the Securiti
December 2, 2022	10-12B/A	As filed with the Securities and Exchange Commission on December 2, 2022. As filed with the Securities and Exchange Commission on December 2, 2022. File No. 001-41528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 GE Healthcare Holding LLC* (Exact name of registrant as specified in its charter) Delaware 8
December 2, 2022	EX-99.2	Form of Notice of Internet Availability of Information Statement Materials. Exhibit 99.2 Shareowner Services P.O. Box 64945 St. Paul, MN 55164-0945 GENERAL ELECTRIC COMPANY NOTICE OF MATERIALS FOR GENERAL ELECTRIC COMPANY SHAREHOLDERS Important Notice Regarding the Availability of Materials. You are receiving this communication because you hold common shares in General Electric Company (?GE?). GE has released informational materials regarding its spin-off of its Healthcar
December 2, 2022	EX-99.1	Exhibit 99.1 Table of Contents Exhibit 99.1 , 2022 Dear GE Shareholders: In November 2021, we announced our plans to transform GE by forming three independent, investment-grade industry leaders with sustainability at their core. We will spin off GE HealthCare first in early 2023; combine our renewable energy, power, and digital businesses into one business, GE Vernova, to be launched as an independent, publicl
November 18, 2022	EX-10.16	Amended Offer Letter with Peter J. Arduini, dated November 16, 2022 (incorporated by reference to Exhibit 10.16 to the Registrant’s Amendment No. 2 to Form 10 filed with the SEC on November 18, 2022). Exhibit 10.16 GE Corporate L. Kevin Cox Chief Human Resources Officer November 16, 2022 Mr. Peter Arduini GE Healthcare Holding LLC 500 W. Monroe Street Chicago, IL 60601 Dear Pete: On behalf of General Electric Company (?GE?), it is with pleasure that I extend this offer for Appointment as President and Chief Executive Officer of GE HealthCare Technologies, Inc. (the ?Company? or ?GE HealthCare?)
November 18, 2022	EX-99.1	Preliminary Information Statement. Table of Contents Exhibit 99.1 , 2022 Dear GE Shareholders: In November 2021, we announced our plans to transform GE by forming three independent, investment-grade industry leaders with sustainability at their core. We will spin off GE HealthCare first in early 2023; combine our renewable energy, power, and digital businesses into one business, GE Vernova, to be launched as an independent, publicl
November 18, 2022	10-12B/A	As filed with the Securities and Exchange Commission on November 18, 2022. 10-12B/A 1 d379971d1012ba.htm 10-12B/A As filed with the Securities and Exchange Commission on November 18, 2022. File No. 001-41528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 GE Healthcare Holding LLC* (Exact name of registrant
November 7, 2022	EX-99.1	Preliminary Information Statement. Table of Contents Exhibit 99.1 , 2022 Dear GE Shareholders: In November 2021, we announced our plans to transform GE by forming three independent, investment-grade industry leaders with sustainability at their core. We will spin off GE HealthCare first in early 2023; combine our renewable energy, power, and digital businesses into one business, GE Vernova, to be launched as an independent, publicl
November 7, 2022	EX-10.10	Credit Agreement, dated as of November 4, 2022, by and among the Registrant, as the borrower, the lenders from time to time party thereto and Citibank, N.A., as administrative agent (incorporated by reference to Exhibit 10.10 to the Registrant’s Amendment No. 1 to Form 10 filed with the SEC on November 7, 2022). Exhibit 10.10 Execution CREDIT AGREEMENT dated as of November 4, 2022 Among GE HEALTHCARE HOLDING LLC, as the Borrower, CITIBANK, N.A., as the Administrative Agent, And The Lenders Party Hereto $2,500,000,000 REVOLVING DOLLAR AND EURO CREDIT FACILITY CITIBANK, N.A., BOFA SECURITIES, INC., BNP PARIBAS SECURITIES CORP., GOLDMAN SACHS BANK USA and MORGAN STANLEY SENIOR FUNDING, INC., as Joint Bookrun
November 7, 2022	EX-10.19	Performance Stock Unit Grant Agreement for Peter J. Arduini, dated February 23, 2022 (incorporated by reference to Exhibit 10.19 to the Registrant’s Amendment No. 1 to Form 10 filed with the SEC on November 7, 2022). Exhibit 10.19 February 23, 2022 Equity Grant Agreement GE 2007 Long-Term Incentive Plan (as amended and restated) GE Performance Stock Unit Grant Agreement (?Grant Agreement?) For Peter Arduini (?Grantee?) Grant Date PSUs Granted Performance Period February 23, 2022 51,948* January 1, 2022 - December 31, 2024 (target) * Actual number of Shares delivered to be between 0% and 150% of target based on
November 7, 2022	10-12B/A	As filed with the Securities and Exchange Commission on November 7, 2022. 10-12B/A 1 d379971d1012ba.htm 10-12B/A As filed with the Securities and Exchange Commission on November 7, 2022. File No. 001-41528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 GE Healthcare Holding LLC* (Exact name of registrant
November 7, 2022	EX-10.17	Performance Share Grant Agreement for H. Lawrence Culp, Jr., dated August 18, 2020 (incorporated by reference to Exhibit 10.17 to the Registrant’s Amendment No. 1 to Form 10 filed with the SEC on November 7, 2022). Exhibit 10.17 August 18, 2020 Equity Grant Agreement GE Performance Share Grant Agreement For H. Lawrence Culp, Jr. (the ?Grantee?) Grant Date Performance Shares Granted Restriction Lapse Date August 18, 2020 9,295,352 Granted, at Target (the ?Target Performance Shares?) The earliest to occur of (w) August 17, 2025, (x) a Change in Control (as defined in the Employment Agreement dated as of Octobe
November 7, 2022	EX-10.14	Form of GE HealthCare Mirror 1990 Long-Term Incentive Plan Exhibit 10.14 GE HEALTHCARE TECHNOLOGIES INC. MIRROR 1990 LONG-TERM INCENTIVE PLAN SECTION 1. PURPOSE The purpose of this GE HealthCare Technologies Inc. Mirror 1990 Long-Term Incentive Plan (the ?Plan?) is to assume on the Effective Date (as defined below), as a result of the spin-off of GE?s healthcare business (the ?Spin-Off?), awards in GE HealthCare Technologies Inc. (the ?Company?) as a resu
November 7, 2022	EX-10.12	Form of GE HealthCare Mirror 2022 Long-Term Incentive Plan. Exhibit 10.12 GE HEALTHCARE TECHNOLOGIES INC. MIRROR 2022 LONG-TERM INCENTIVE PLAN Section I. Purpose The purpose of this GE HealthCare Technologies Inc. Mirror 2022 Long-Term Incentive Plan is to assume on the Effective Date (as defined below), as a result of the spin-off of GE?s healthcare business (the ?Spin-Off?), awards in GE HealthCare Technologies Inc. as a result of the conversion of award
November 7, 2022	EX-10.3	Form of Employee Matters Agreement, by and between General Electric Company and the registrant. EX-10.3 5 d379971dex103.htm EX-10.3 Exhibit 10.3 EMPLOYEE MATTERS AGREEMENT THIS EMPLOYEE MATTERS AGREEMENT (“Employee Matters Agreement”) is executed effective as of [●], 202[●], by and between General Electric Company, a New York corporation (“Parent”) and GE HealthCare Technologies Inc., a Delaware corporation (“SpinCo”) (collectively, the “Parties”). WHEREAS, the Parties have entered into a Se

GB:0ADL
CO:GEHC
MX:GEHC
DE:L0T	€ 63.11
IT:1GEHC	€ 63.60

GEHC / GE HealthCare Technologies Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings